dalfopristin and Diabetes-Mellitus--Type-1

dalfopristin has been researched along with Diabetes-Mellitus--Type-1* in 1 studies

Other Studies

1 other study(ies) available for dalfopristin and Diabetes-Mellitus--Type-1

Article	Year
Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. Southern medical journal, 2003, Volume: 96, Issue:8 A 56-year-old man with diabetes mellitus and cadaveric renal transplantation had vancomycin-resistant Enterococcus faecium tricuspid valve endocarditis. Relapse followed 6 weeks of treatment with intravenous gentamicin and high-dose ampicillin. On the basis of previous data suggesting the potential for synergistic activity of quinupristin/dalfopristin plus high-dose ampicillin, therapy with this combination was administered for 63 days. Cure was achieved and later confirmed at 2-year follow-up. Topics: Ampicillin; Anti-Bacterial Agents; Bacteremia; Diabetes Mellitus, Type 1; Drug Resistance, Bacterial; Drug Therapy, Combination; Endocarditis, Bacterial; Enterococcus faecium; Gentamicins; Gram-Positive Bacterial Infections; Humans; Immunocompromised Host; Kidney Transplantation; Male; Microbial Sensitivity Tests; Middle Aged; Penicillins; Recurrence; Treatment Outcome; Vancomycin Resistance; Virginiamycin	2003

Article

Year

Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin.

Southern medical journal, 2003, Volume: 96, Issue:8

A 56-year-old man with diabetes mellitus and cadaveric renal transplantation had vancomycin-resistant Enterococcus faecium tricuspid valve endocarditis. Relapse followed 6 weeks of treatment with intravenous gentamicin and high-dose ampicillin. On the basis of previous data suggesting the potential for synergistic activity of quinupristin/dalfopristin plus high-dose ampicillin, therapy with this combination was administered for 63 days. Cure was achieved and later confirmed at 2-year follow-up.

Topics: Ampicillin; Anti-Bacterial Agents; Bacteremia; Diabetes Mellitus, Type 1; Drug Resistance, Bacterial; Drug Therapy, Combination; Endocarditis, Bacterial; Enterococcus faecium; Gentamicins; Gram-Positive Bacterial Infections; Humans; Immunocompromised Host; Kidney Transplantation; Male; Microbial Sensitivity Tests; Middle Aged; Penicillins; Recurrence; Treatment Outcome; Vancomycin Resistance; Virginiamycin

2003